Vaxxilon discovers and develops novel vaccines for infectious diseases based on the scientific insights and research of Prof. P. Seeberger (Max Planck Society) and G. de Libero (University of Basel). Vaxxilon is advancing several candidates using homogeneous, synthetically produced antigens. The lead projects include prophylactic vaccines targeting AMR pathogens such as C. Diff and Klebsiella pneumoniae.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2015
  • Number of employees in Switzerland
    1-9
Key business